

Resource Summary Report

Generated by [NIF](#) on Aug 24, 2026

YAP (63.7)

RRID:AB_1131430

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-101199, RRID:AB_1131430

Antibody Information

URL: http://antibodyregistry.org/AB_1131430

Proper Citation: Santa Cruz Biotechnology Cat# sc-101199, RRID:AB_1131430

Target Antigen: YAP (63.7)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: ELISA; Immunohistochemistry; Western Blot; Immunofluorescence; Immunocytochemistry; WB, IP, IF, IHC(P), ELISA

Antibody Name: YAP (63.7)

Description: This monoclonal targets YAP (63.7)

Target Organism: mouse, human

Antibody ID: AB_1131430

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-101199

Record Creation Time: 20250820T050112+0000

Record Last Update: 20250820T203404+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for YAP (63.7).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 113 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Abdelfattah N, et al. (2026) Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma. Cancer cell, 44(4), 760.

Lee SJ, et al. (2026) Hypoxia restores the acidosis-induced inhibition of cancer cell dissemination. Cell reports, 45(2), 116970.

Peng H, et al. (2026) Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. Nature communications, 17(1).

Amorim R, et al. (2026) Mitochondria-targeted antioxidant AntiOxBEN2 prevents metabolic dysfunction-associated steatotic liver disease (MASLD) by enhancing fatty acid oxidation and mitochondrial bioenergetics. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119022.

Qin Z, et al. (2026) Cadherin-engineered microspheres enable scalable biofabrication of multilineage liver organoids. Trends in biotechnology.

Mu R, et al. (2026) Yap mediates Hippo signaling to balance proliferation and differentiation in the developing glandular stomach epithelium. Cell reports, 45(7), 117644.

Venhuizen AJ, et al. (2026) Hepatocellular carcinoma-linked AXIN1 mutations drive low Wnt/?-catenin activity enabling niche-independent growth and YAP/TAZ signaling. iScience, 29(1), 114501.

Ferrick KR, et al. (2026) Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio. Communications biology, 9(1).

Packirisamy S, et al. (2026) ECM-Stiffness Mediated Persistent Fibroblast Activation Requires Integrin and Formin Dependent Chromatin Remodeling. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(34), e17631.

Fruzzetti F, et al. (2026) Improving Nonviral Gene Delivery by Activating Mechanosensing-Dependent Endocytic Pathways. *ACS applied materials & interfaces*.

Mukherjee A, et al. (2026) Membrane potential mediates the cellular response to mechanical pressure. *Cell*, 189(1), 143.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. *Cancer research*, 86(12), 2860.

Peng L, et al. (2026) Sevoflurane ameliorates cerebral ischemia-reperfusion injury by modulating mitochondrial dynamics and attenuating apoptosis via Shh-YAP1 signaling pathway. *Molecular brain*, 19(1).

Shibata S, et al. (2026) Rotational trophoblast organoids reveal biomechanical regulation of trophoblast differentiation. *Cell reports*, 45(7), 117637.

Akinpelu A, et al. (2026) Hydrostatic pressure reduces the mechanosensitivity of cell migration. *Science advances*, 12(26), eaed0981.

Creixell M, et al. (2026) AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer. *Cell reports*, 45(7), 117717.

Li S, et al. (2025) Glutamine synthetase modulates YAP activation by stabilizing LATS under glutamine homeostasis. *Cell reports*, 44(12), 116620.

Ahmad ST, et al. (2025) Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target. *Cancer cell*, 43(6), 1141.

Cao X, et al. (2025) RIPK4 promotes epidermal differentiation through phase separation and activation of LATS1/2. *Developmental cell*.

Rominger MC, et al. (2025) Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state. *Cell reports*, 44(10), 116185.